Posted by Michael Wonder on 18 Nov 2019
National MS Society responds to price of new Biogen/Alkermes MS medication Vumerity
13 November 2019 - The FDA recently approved a new medication for relapsing MS, Vumerity, by Biogen and Alkermes.
Biogen, which has the license to commercialise the drug, released this statement along with announcing the price:
“We’ve made the decision to launch Vumerity in the US with the lowest annual WAC price for oral MS disease-modifying therapies at an annualised price of $88,000.”
The National MS Society is releasing this statement:
“Vumerity is an efficacious and tolerable treatment option for people with relapsing MS, but being priced only $500 lower than the least expensive oral disease modifying treatment, does not show the commitment to affordable access that we had hoped,” said Bari Talente, executive vice president, advocacy, National MS Society.
